{"filing":{"accession_number":"0001171843-26-006705","cik":"0002027329","ticker":"OPTHF","company_name":"Optimi Health Corp.","form":"6-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"f6k_102026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2027329/000117184326006705/f6k_102026.htm"},"events":[{"id":36295,"run_id":33462,"accession_number":"0001171843-26-006705","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Optimi announces completion of MDMA production batch to supply three programs: a proposed Phase 3 PTSD trial in Canada, a clinical trial in Israel with MAPS, and commercial export to Australia. This is a material operational milestone disclosing manufacturing completion, regulatory progress (Health Canada Drug Establishment Licence, Australian import permits), and advancement of clinical and commercial programs. While not a discrete M\u0026A, financing, or executive event, the production completion and multi-jurisdictional supply arrangements represent material operational progress for a pharmaceutical manufacturer.","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-10-20","form":"6-K","submitted_at":null,"items":[{"id":40661,"accession_number":"0001171843-26-006705","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Optimi announces completion of MDMA production batch to supply three programs: a proposed Phase 3 PTSD trial in Canada, a clinical trial in Israel with MAPS, and commercial export to Australia. This is a material operational milestone disclosing manufacturing completion, regulatory progress (Health Canada Drug Establishment Licence, Australian import permits), and advancement of clinical and commercial programs. While not a discrete M\u0026A, financing, or executive event, the production completion and multi-jurisdictional supply arrangements represent material operational progress for a pharmaceutical manufacturer.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:30:37.866162+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40661,"accession_number":"0001171843-26-006705","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Optimi announces completion of MDMA production batch to supply three programs: a proposed Phase 3 PTSD trial in Canada, a clinical trial in Israel with MAPS, and commercial export to Australia. This is a material operational milestone disclosing manufacturing completion, regulatory progress (Health Canada Drug Establishment Licence, Australian import permits), and advancement of clinical and commercial programs. While not a discrete M\u0026A, financing, or executive event, the production completion and multi-jurisdictional supply arrangements represent material operational progress for a pharmaceutical manufacturer.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:30:37.866162+00:00","company_name":"Optimi Health Corp.","ticker":"OPTHF","filing_date":"2026-10-20"}]}